Read More Pharma Industry News Bajaj Healthcare (NSE: BAJAJHCARE) rallies 16% on Cenobamate approval milestone BAJAJHCARE surged on India’s first Cenobamate recommendation. Final approval and launch economics must now justify the ₹1,183 crore valuation. bySrinathJuly 1, 2026